Cargando…
Silencing E3 Ubiqutin ligase ITCH as a potential therapy to enhance chemotherapy efficacy in p53 mutant neuroblastoma cells
P53 mutations are responsible for drug-resistance of tumour cells which impacts on the efficacy of treatment. Alternative tumour suppressor pathways need to be explored to treat p53- deficient tumours. The E3 ubiquitin ligase, ITCH, negatively regulates the tumour suppressor protein TP73, providing...
Autores principales: | Meng, Jinhong, Tagalakis, Aristides D., Hart, Stephen L. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6978385/ https://www.ncbi.nlm.nih.gov/pubmed/31974512 http://dx.doi.org/10.1038/s41598-020-57854-6 |
Ejemplares similares
-
ITCH E3 ligase in ATM network
por: Stagni, Venturina, et al.
Publicado: (2014) -
p62 links the autophagy pathway and the ubiqutin–proteasome system upon ubiquitinated protein degradation
por: Liu, Wei Jing, et al.
Publicado: (2016) -
The E3 ubiquitin ligase Itch is required for B-cell development
por: Liu, Xiaoling, et al.
Publicado: (2019) -
UBE4B interacts with the ITCH E3 ubiquitin ligase to induce Ku70 and c-FLIPL polyubiquitination and enhanced neuroblastoma apoptosis
por: Le Clorennec, Christophe, et al.
Publicado: (2023) -
ATM kinase activity modulates ITCH E3-ubiquitin ligase activity
por: Santini, Simonetta, et al.
Publicado: (2013)